Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other Non-Current Liabilities: 2019-2020

Historic Other Non-Current Liabilities for Keros Therapeutics (KROS) over the last 2 years, with Dec 2020 value amounting to $62,000.

  • Keros Therapeutics' Other Non-Current Liabilities fell 79.22% to $16,000 in Q3 2021 from the same period last year, while for Sep 2021 it was $16,000, marking a year-over-year decrease of 79.22%. This contributed to the annual value of $62,000 for FY2020, which is 47.90% down from last year.
  • Per Keros Therapeutics' latest filing, its Other Non-Current Liabilities stood at $62,000 for FY2020, which was down 47.90% from $119,000 recorded in FY2019.
  • Keros Therapeutics' 5-year Other Non-Current Liabilities high stood at $119,000 for FY2019, and its period low was $62,000 during FY2020.
  • In the last 2 years, Keros Therapeutics' Other Non-Current Liabilities had a median value of $90,500 in 2019 and averaged $90,500.
  • Data for Keros Therapeutics' Other Non-Current Liabilities shows a maximum YoY plummeted of 47.90% (in 2020) over the last 5 years.
  • Over the past 2 years, Keros Therapeutics' Other Non-Current Liabilities (Yearly) stood at $119,000 in 2019, then crashed by 47.90% to $62,000 in 2020.